Chaidos et al. demonstrated that the ratios of CD19−CD138− pre-PC (plasma cell) myeloma cell, CD19−CD138low myeloma cell, and CD19-CD138high myeloma cell were changed via therapeutic selection and pre-PC myeloma showed drug resistance [153]. This evidence concerns the gene CD19 and plasma cell myeloma.